<html>
<head>
<title>ACP </title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<META NAME="Table1">
<META NAME="Ref1">
<META NAME="Ref1">
</head>

<body bgcolor="B6b6b6">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="214d7b" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><a name="Top"></a><img src="../Assets/ISHThiazidestitle.gif" width="580" height="50"></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_ISHandThiazides.html"><img src="../Assets/ACP1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_ISHandThiazides.html"><img src="../Assets/ACP2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_ISHandThiazides.html"><img src="../Assets/ACP3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_ISHandThiazides.html"><img src="../Assets/ACP4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_ISHandThiazides.html"><img src="../Assets/ACP5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_ISHandThiazides.html"><img src="../Assets/ACP6.gif" width="121" height="37" name="VA" border="0"></a></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/ACPheader.gif" width="330" height="50" align="baseline"><img src="../Assets/ACPheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="746" height="469" bgcolor="ffffff"> 
            <div align="center"><br>
              <table width="90%" border="1" bordercolor="#6699CC">
                <tr> 
                  <td colspan="4" bgcolor="#336699"> 
<div align="center"><font face="Times New Roman, Times, serif" size="3" color="#FFFFFF"><b>Click 
                      on the study below</b></font> <font face="Times New Roman, Times, serif" size="3" color="#FFFFFF"><b>to 
                      view</b></font></div></td>
                </tr>
                <tr> 
                  <td width="25%"> 
<div align="center"><a href="#Messerli"><font color="#336699">Messerli 1998</font></a> 
                    </div></td>
                  <td width="25%">
                    <div align="center"><a href="#MRC"><font color="#336699">MRC 
                      1992</font></a> </div></td>
                  <td width="25%">
                    <div align="center"><a href="#SHEP"><font color="#336699">SHEP 
                      1991</font></a> </div></td>
                  <td> <div align="center"><a href="#Staessen"><font color="#336699">Staessen 
                      2000</font></a></div></td>
                </tr>
              </table>
<br>
              <table width="90%" border="0">
                <tr>
                  <td> <p class="BEsection"><font color="3399cc"><a name="Messerli"></a>Therapeutics</font></p>
                    <table width="100%" border="0" bgcolor="6699cc">
                      <tr>
                        <td><font size="4"><strong><a name="review.diureticsaremoreefficaciousthanb.blockersasfirst.linetherapyforelderlypatientswithhypertension"></a>Review: 
                          Diuretics are more efficacious than &beta;-blockers 
                          as first-line therapy for elderly patients with hypertension</strong></font></td>
                      </tr>
                    </table>
                    <P CLASS="ACPSource">ACP Journal Club. 1998 Nov-Dec; 129:60.<BR>
                      Evidence-Based Medicine. 1998 Nov-Dec;3:174.</p>
                    <P CLASS="Citation">Messerli FH, Grossman E, Goldbourt U. 
                      <B>Are </B>&beta;<B>-blockers efficacious as first-line 
                      therapy for hypertension in the elderly? A systematic review.</B> 
                      JAMA. 1998 Jun 17;279:1903-7.</p>
                    <HR SIZE=2 COLOR=#3399CC> 
                    <P CLASS="AbsHd"><font color="3399cc">Question</font></p>
                    <P CLASS="AbsTxt">In elderly patients with hypertension, are 
                      &beta;-blockers as efficacious as diuretics for cardiovascular 
                      morbidity and mortality and all-cause mortality?</p>
                    <P CLASS="AbsHd"><font color="3399cc">Data sources</font></p>
                    <P CLASS="AbsTxt">English-language studies were identified 
                      by searching MEDLINE (January 1966 to January 1998) using 
                      the search terms hypertension, elderly or aged or geriatric, 
                      cerebrovascular or cardiovascular disease, and morbidity 
                      or mortality and by searching CARDLINE (1986 to 1997). Bibliographies 
                      of relevant papers were also reviewed.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Study selection</font></p>
                    <P CLASS="AbsTxt">Studies were selected if they were randomized 
                      trials &ge; 1 year duration, used diuretics or &beta;-blockers 
                      as first-line agents, and reported effects on morbidity 
                      or mortality in patients &ge; 60 years of age.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Data extraction</font></p>
                    <P CLASS="AbsTxt">Data were extracted on patient blood pressure 
                      response to the first-line drug, coronary heart disease 
                      (CHD), cerebrovascular events, cardiovascular mortality, 
                      and all-cause mortality.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Main results</font></p>
                    <P CLASS="AbsTxt">12 studies met the selection criteria; 2 
                      studies that focused on patients who survived a stroke were 
                      excluded from the analysis. Meta-analysis was done using 
                      intention-to-treat results from individual studies. Diuretics 
                      reduced cerebrovascular events; CHD; and stroke, cardiovascular, 
                      and all-cause mortality, whereas treatment with &beta;-blockers 
                      reduced only cerebrovascular events (Table).</p>
                    <P CLASS="AbsHd"><font color="3399cc">Conclusions</font></p>
                    <P CLASS="AbsTxt">In elderly patients with hypertension, first-line 
                      diuretics reduced cerebrovascular events; coronary heart 
                      disease; and stroke, cardiovascular, and all-cause mortality. 
                      First-line &beta;-blockers reduced only cerebrovascular 
                      events.</p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="Grant">Source of funding: 
                      Not stated.</p>
                    <P CLASS="Reprint">For correspondence: Dr. F.H. Messerli, 
                      Ochsner Clinic, Section on Hypertension, 1514 Jefferson 
                      Highway, New Orleans, LA 70121, USA. FAX 504-842-4104.</p>
                    <HR SIZE=2 COLOR=#3399CC>
                    <P CLASS="TablTitl">First-line diuretics and &beta;-blockers 
                      in elderly hypertensive patients at an approximate mean 
                      of 5-years follow-up*</p>
                    <TABLE BORDER=1 BORDERCOLOR=#CCCCCC CELLBORDER=#CCCCCC CELLSPACING=0 CELLPADDING=4>
                      <tr valign=top> 
                        <td> <P CLASS="ColHdL">Outcomes&nbsp;</td>
                        <td colspan=2> <P class="ColHdC">First-line diuretics&nbsp;</td>
                        <td colspan=2> <P class="ColHdC">&beta;-blockers&nbsp;</td>
                      </tr>
                      <tr valign=top> 
                        <td> <P CLASS="ColHdL">&nbsp;</td>
                        <td> <P CLASS="ColHdC">Number of trials&nbsp;</td>
                        <td> <P CLASS="ColHdC">Pooled odds ratios (95% CI)&nbsp;</td>
                        <td> <P CLASS="ColHdC">Number of trials&nbsp;</td>
                        <td> <P CLASS="ColHdC">Pooled odds ratios (CI)&nbsp;</td>
                      </tr>
                      <tr valign=top> 
                        <td> <P CLASS="CellTxtL">Cerebrovascular events&nbsp;</td>
                        <td> <P CLASS="CellTxtC">8&nbsp;</td>
                        <td> <P CLASS="CellTxtC">0.61 (0.51 to 0.72)&nbsp;</td>
                        <td> <P CLASS="CellTxtC">2&nbsp;</td>
                        <td> <P CLASS="CellTxtC">0.74 (0.57 to 0.98)&nbsp;</td>
                      </tr>
                      <tr valign=top> 
                        <td> <P CLASS="CellTxtL">Coronary heart disease&nbsp;</td>
                        <td> <P CLASS="CellTxtC">8&nbsp;</td>
                        <td> <P CLASS="CellTxtC">0.74 (0.64 to 0.85)&nbsp;</td>
                        <td> <P CLASS="CellTxtC">2&nbsp;</td>
                        <td> <P CLASS="CellTxtC">1.01* (0.80 to 1.29)&nbsp;</td>
                      </tr>
                      <tr valign=top> 
                        <td> <P CLASS="CellTxtL">Stroke mortality&nbsp;</td>
                        <td> <P CLASS="CellTxtC">7&nbsp;</td>
                        <td> <P CLASS="CellTxtC">0.67 (0.49 to 0.90)&nbsp;</td>
                        <td> <P CLASS="CellTxtC">2&nbsp;</td>
                        <td> <P CLASS="CellTxtC">0.76* (0.48 to 1.22)&nbsp;</td>
                      </tr>
                      <tr valign=top> 
                        <td> <P CLASS="CellTxtL">Cardiovascular mortality&nbsp;</td>
                        <td> <P CLASS="CellTxtC">7&nbsp;</td>
                        <td> <P CLASS="CellTxtC">0.75 (0.64 to 0.87)&nbsp;</td>
                        <td> <P CLASS="CellTxtC">2&nbsp;</td>
                        <td> <P CLASS="CellTxtC">0.98* (0.78 to 1.23)&nbsp;</td>
                      </tr>
                      <tr valign=top> 
                        <td> <P CLASS="CellTxtL">All-cause mortality&nbsp;</td>
                        <td> <P CLASS="CellTxtC">7&nbsp;</td>
                        <td> <P CLASS="CellTxtC">0.86 (0.77 to 0.96)&nbsp;</td>
                        <td> <P CLASS="CellTxtC">2&nbsp;</td>
                        <td> <P CLASS="CellTxtC">1.05* (0.88 to 1.25)&nbsp;</td>
                      </tr>
                    </table>
                    <br> <P CLASS="TablFootn">*Not significant.</p>
                    <HR SIZE=2 COLOR=#3399CC> 
                    <P CLASS="CmHd"><font color="3399cc">Commentary</font></p>
                    <P CLASS="CmTxt">Thiazide or thiazide-like diuretics are inexpensive 
                      and have few contraindications or major adverse effects 
                      when used at low doses. They are especially effective in 
                      older persons with hypertension, including those with isolated 
                      systolic hypertension. In conjunction with nonpharmacologic 
                      interventions, diuretics have been shown to improve quality 
                      of life (1). Thiazides infrequently cause gout or sexual 
                      dysfunction in men, which are important but reversible consequences 
                      that demand awareness by prescriber and patient. Low-dose 
                      thiazide diuretic therapy has been endorsed by the Joint 
                      National Committee on Prevention, Detection, Evaluation, 
                      and Treatment of High Blood Pressure (2) as first-line monotherapy 
                      in hypertensive older persons. &beta;-blockers, although 
                      highly effective in symptom management of ischemic disease 
                      and in secondary prevention after myocardial infarction, 
                      have a secondary role for hypertension in the elderly and 
                      are not recommended as monotherapy.</p>
                    <P CLASS="CmTxt">We should reflect on reasons for poor utilization 
                      of thiazide diuretics despite the class attributes. The 
                      issues are even more important in the context of an aging 
                      population with an increasing prevalence ofhypertension, 
                      a need for the simplicity of once-daily therapy with excellent 
                      24-hour blood pressure control, and the pervasive concern 
                      of cost-effectiveness. There is a lack of pharmaceutical 
                      promotion of thiazides and a prevailing sense that thiazides 
                      are &quot;old-fashioned.&quot; Prescriber concerns about 
                      causing hypokalemia, hyperuricemia, dyslipidemia, glucose 
                      intolerance, and cardiac arrhythmias relate to an earlier 
                      era when therapeutic choice was limited and individual drugs 
                      were commonly prescribed in excessive doses.</p>
                    <P CLASS="CmTxt">Altering negative attitudes to thiazides 
                      in the context of many effective, well-tolerated, newer, 
                      heavily promoted, and more expensive antihypertensive drugs 
                      will not be easy. More extensive use of low-dose diuretics 
                      surely has a place in initial therapy for elderly persons 
                      with hypertension and as part of combination treatments 
                      when low-dose diuretics do not sufficiently lower blood 
                      pressure.</p>
                    <P CLASS="CmAuth1">S. George Carruthers, MD<BR>
                      University of Western Ontario<BR>
                      London, Ontario, Canada</p>
                    <HR SIZE=2 COLOR=#3399CC>
                    <br>
                    <table width="100%" border="0" bgcolor="6699cc">
                      <tr> 
                        <td><strong>References</strong></td>
                      </tr>
                    </table>
                    <P CLASS="CmRef">1. <B>Neaton JD, Grimm RH Jr, Prineas RJ,et 
                      al. </B>Treatment of Mild Hypertension Study. Final results. 
                      Treatment of Mild Hypertension Study Research Group. JAMA. 
                      1993;270:713-24.</p>
                    <P CLASS="CmRef">2. The sixth report of the Joint National 
                      Committee on prevention, detection, evaluation, and treatment 
                      of high blood pressure. Arch Intern Med. 1997;157:2413-46.</p>
                    <P align="center" CLASS="CmRef"><strong>Reprinted with permission<br>
                      &copy; American College of Physicians- American Society 
                      of Internal Medicine</strong></p>
                    <P align="left" CLASS="CmRef"><br>
                      <a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a><br>
                      <br>
                      <a name="MRC"></a> </p>
                    <P CLASS="BEsection"><font color="3399cc">Therapeutics</font></p>
                    <table width="100%" border="0" bgcolor="6699cc">
                      <tr> 
                        <td><strong><font size="4"><a name="acp.acpjc.1992.hydro095"></a>Hydrochlorothiazide 
                          and amiloride reduced the risk for stroke, coronary 
                          events, and cardiovascular events in hypertensive older 
                          adults</font></strong></td>
                      </tr>
                    </table>
                    <P CLASS="ACPSource">ACP Journal Club. 1992 July-Aug;117:1. 
                      <a href="Revised%20MRC%20files/RE928NLH.html" target="_blank">Revised 
                      November 1997</a></p>
                    <P CLASS="Citation">MRC Working Party. <B>Medical Research 
                      Council trial of treatment of hypertension in older adults: 
                      principal results.</B> BMJ. 1992 Feb 15;304:405-12.</p>
                    <HR SIZE=2 COLOR=#3399CC> 
                    <P CLASS="AbsHd"><font color="3399cc">Objective</font></p>
                    <P CLASS="AbsTxt">To determine whether treatment reduces the 
                      risk for stroke, coronary heart disease, and death from 
                      all causes in hypertensive adults aged 65 to 74 years.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Design</font></p>
                    <P CLASS="AbsTxt">Randomized, single-blind, placebo-controlled 
                      trial (mean follow-up of 5.8 y).</p>
                    <P CLASS="AbsHd"><font color="3399cc">Setting</font></p>
                    <P CLASS="AbsTxt">226 general practices in England, Scotland, 
                      and Wales.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Patients</font></p>
                    <P CLASS="AbsTxt">4396 patients (mean age, 70 y) with hypertension 
                      (defined as a mean systolic blood pressure of 160 to 209 
                      mm Hg and mean diastolic blood pressure &lt; 115 mm Hg during 
                      an 8-wk run-in period) were included. Exclusion criteria 
                      were secondary hypertension; taking antihypertensive medication; 
                      cardiac failure; receiving treatment for angina pectoris; 
                      myocardial infarction or stroke within 3 months; impaired 
                      renal function; diabetes; asthma; or a serum potassium level 
                      of &le; 3.4 mmol/L or &gt; 5.0 mmol/L. 25% of the patients 
                      were lost to follow-up.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Intervention</font></p>
                    <P CLASS="AbsTxt">Patients were assigned to atenolol, 50 mg 
                      daily (<I>n</I> = 1102); hydrochlorothiazide, 25 mg or 50 
                      mg daily, plus amiloride, 2.5 mg or 5.0 mg daily (<I>n</I> 
                      = 1081); or placebo (<I>n</I> = 2213). Beginning in 1985, 
                      all patients assigned to the diuretic regimen received the 
                      lower dose. Drug regimens for those on active treatment 
                      were modified to achieve individual target blood pressures.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Main outcome measures</font></p>
                    <P CLASS="AbsTxt">Stroke, coronary events, and death from 
                      all causes. Analysis was by intention-to-treat.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Main results</font></p>
                    <P CLASS="AbsTxt">Compared with placebo, patients receiving 
                      active treatment (diuretic and &beta;-blocker groups) had 
                      a 25% reduction in stroke (95% CI 3% to 42%) and a 17% reduction 
                      in all cardiovascular events (CI 2% to 29%). When compared 
                      with placebo and after adjustment for baseline factors, 
                      the diuretic group had a 31% reduction in stroke (CI 3% 
                      to 51%); a 44% reduction in coronary events (CI 21% to 60%); 
                      and a 35% reduction in all cardiovascular events (CI 17% 
                      to 49%). None of these end points was significant in the 
                      &beta;-blocker group and the rates of coronary events and 
                      all cardiovascular events were higher than in the diuretic 
                      group.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Conclusion</font></p>
                    <P CLASS="AbsTxt">Hydrochlorothiazide and amiloride reduced 
                      the risk for stroke, coronary events, and all cardiovascular 
                      events in older hypertensive adults when compared with atenolol 
                      and placebo.</p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="Grant">Sources of funding: 
                      Medical Research Council; Merck Sharp &amp; Dohme; Imperial 
                      Chemical Industries; Bayer.</p>
                    <P CLASS="Reprint">Address for article reprint: Dr. T.W. Meade, 
                      MRC Epidemiology and Medical Care Unit, Wolfson Institute 
                      of Preventive Medicine, Medical College of St. Bartholomew's 
                      Hospital, London EC1M 6BQ, United Kingdom.</p>
                    <HR SIZE=2 COLOR=#3399CC> 
                    <P CLASS="CmHd"><font color="3399cc">Commentary</font></p>
                    <P CLASS="CmTxt">A decade ago clinicians were debating the 
                      usefulness of treating hypertension in elderly persons. 
                      Although epidemiologic evidence showed a deleterious effect 
                      of hypertension, no clinical trials existed, and it was 
                      possible that side effects would outweigh any benefit. This 
                      article joins several previous studies in convincingly showing 
                      a benefit of treating elevations of systolic and combined 
                      systolic and diastolic hypertension, especially with a diuretic 
                      combination, in persons over 65 years.</p>
                    <P CLASS="CmTxt">Although this study adds weight to the arguments 
                      in favor of active treatment of hypertension in the elderly, 
                      perhaps the most intriguing element is the comparison between 
                      two classes of antihypertensive drug therapy&mdash;thiazide 
                      diuretics with a potassium-sparing agent compared with &beta;-blockade. 
                      Most previous treatment trials have used diuretics as primary 
                      agents. Because &beta;-blockers, calcium antagonists, and 
                      angiotensin-converting enzyme inhibitors are all also commonly 
                      used, it will be useful for future trials to incorporate 
                      randomized comparisons between drugs to help determine the 
                      optimal regimen. This study showed decreased efficacy and 
                      less tolerance for atenolol compared with the diuretic. 
                      The lower antihypertensive efficacy makes it difficult to 
                      interpret the lack of significant effect of the &beta;-blocker 
                      on this trial's primary end points, but this lack of effect 
                      is in line with the results of other trials of &beta;-blockers 
                      in the elderly. The &beta;-blocker group also had more dropouts 
                      than the diuretic group, both for side effects and for inadequate 
                      blood pressure control. I hope that this study will spark 
                      future studies to answer questions directly about the relative 
                      value of different antihypertensive drugs.</p>
                    <P CLASS="CmAuth1">Jay S. Luxenberg, MD<BR>
                      The San Francisco Institute on Aging<BR>
                      San Francisco, California, USA</p>
                    <P align="center" CLASS="CmAuth1"><strong>Reprinted with permission<br>
                      &copy; American College of Physicians- American Society 
                      of Internal Medicine</strong></p>
                    <P CLASS="CmAuth1"><br>
                      <a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a><br>
                      <br>
                      <a name="SHEP"></a> </p>
                    <P CLASS="BEsection"><font color="3399cc">Therapeutics</font></p>
                    <table width="100%" border="0" bgcolor="6699cc">
                      <tr> 
                        <td><strong><font size="4"><a name="acp.acpjc.1991.strok163"></a>Antihypertensive 
                          drugs in stepped doses reduced stroke in elderly patients 
                          with isolated systolic hypertension</font></strong></td>
                      </tr>
                    </table>
                    <P CLASS="ACPSource">ACP Journal Club. 1991 Nov-Dec;115:65.<a href="Revised%20SHEP%20files/RE917777.html" target="_blank"> 
                      Revised November 1996</a></p>
                    <P CLASS="Citation">SHEP Cooperative Research Group. <B>Prevention 
                      of stroke by antihypertensive drug treatment in older persons 
                      with isolated systolic hypertension. Final results of the 
                      Systolic Hypertension in the Elderly Program (SHEP).</B> 
                      JAMA. 1991 Jun 26;265:3255-64.</p>
                    <HR SIZE=2 COLOR=#3399CC> 
                    <P CLASS="AbsHd"><font color="3399cc">Objective</font></p>
                    <P CLASS="AbsTxt">To determine whether antihypertensive drug 
                      treatment reduces the risk for stroke (nonfatal and fatal) 
                      in men and women &ge; 60 years of age with isolated systolic 
                      hypertension.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Design</font></p>
                    <P CLASS="AbsTxt">Randomized, double-blind, placebo-controlled 
                      trial over 5 years.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Setting</font></p>
                    <P CLASS="AbsTxt">Community recruitment to 16 tertiary care 
                      centers.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Patients</font></p>
                    <P CLASS="AbsTxt">4736 persons with isolated systolic hypertension 
                      (mean systolic blood pressure [SBP] &ge; 160 mm Hg and mean 
                      diastolic blood pressure [DBP] &lt; 90 mm Hg) were enrolled 
                      after screening 447 921 persons. 57% were women; 14% were 
                      black; the mean age was 72 years; mean SBP, 170 mm Hg; and 
                      mean DBP, 77 mm Hg; 61 % had abnormal ECGs; 33% entered 
                      after withdrawal of previous antihypertensive agents. Patients 
                      with major medical diseases were excluded. Follow-up was 
                      99.8% and averaged 4.5 years.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Intervention</font></p>
                    <P CLASS="AbsTxt">The goal of therapy was a SBP &lt; 160 mm 
                      Hg and a reduction in SBP of at least 20 mm Hg using the 
                      lowest possible dose of medicine. BP was monitored monthly, 
                      and drug therapy (with active drug or placebo) was adjusted 
                      in 4 consecutive steps: chlorthalidone, 12.5 mg/d; increase 
                      to chlorthalidone, 25mg/d; addition of atenolol, 25 mg/d, 
                      or reserpine, 0.05 mg/d; increase to atenolol, 50 mg/d, 
                      or reserpine, 0.1 mg/d. Any patient with sustained SBP &gt; 
                      220 mm Hg or DBP &gt; 90 mm Hg was given active treatment.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Main outcome measures</font></p>
                    <P CLASS="AbsTxt">Fatal and nonfatal stroke, cardiovascular 
                      events, and mortality.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Main results</font></p>
                    <P CLASS="AbsTxt">At 5 years, 90% of the study group and 44% 
                      of controls were on active treatment. Two thirds of patients 
                      assigned to treatment and one third of controls achieved 
                      the SBP goal. (65 % to 72% vs 32% to 40%) 103 persons (4%) 
                      assigned to treatment had strokes (10 fatal) compared with 
                      159 (7%) in the control group (14 fatal){<I>P </I>&lt; 0.001}* 
                      {This absolute risk reduction (ARR) of 3% means that 43 
                      patients would need to be treated (NNT) with antihypertensive 
                      drug treatment (compared with placebo) to prevent 1 additional 
                      stroke, 95% CI 27 to 95; the relative risk reduction (RRR) 
                      was 35%, CI 17% to 49%}.* Fewer patients in the treatment 
                      group had cardiovascular disease {12% vs 17%, <I>P</I> &lt; 
                      0.001; ARR 5%, NNT 19, CI 14 to 31; RRR 30%, CI 20% to 39%}*. 
                      Fewer deaths occurred in the treatment group but the difference 
                      did not reach statistically significant (9% vs 10%, <I>P</I> 
                      = 0.2) {ARR 1%, CI -0.5% to 2.9%}.*</p>
                    <P CLASS="AbsHd"><font color="3399cc">Conclusion</font></p>
                    <P CLASS="AbsTxt">Stepped-care treatment with chlorthalidone, 
                      and atenolol or reserpine if required, of persons &ge; 60 
                      years of age with isolated systolic hypertension reduced 
                      strokes by 36% and had other favorable cardiovascular effects.</p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="Grant">Sources of funding: 
                      National Heart, Lung, and Blood Institute and National Institute 
                      on Aging.</p>
                    <P CLASS="Reprint">Address for article reprint: Dr. J. L. 
                      Probstfield, Division of Epidemiology and Clinical Applications, 
                      National Heart, Lung, and Blood Institute, Federal Building, 
                      Room 5C-10B, 7550 Wisconsin Avenue, Bethesda, MD 20892, 
                      USA.</p>
                    <P CLASS="AbsFootn">*Numbers calculated from data in article.</p>
                    <HR SIZE=2 COLOR=#3399CC> 
                    <P CLASS="CmHd"><font color="3399cc">Commentary</font></p>
                    <P CLASS="CmTxt">This study is impressive for its size, scientific 
                      rigor, and favorable results. Many physicians have been 
                      concerned with the risk of treating elderly persons with 
                      isolated systolic hypertension, especially because a J- 
                      or U-shaped relation between diastolic blood pressure and 
                      mortality has been described (1). This study lays those 
                      concerns to rest.</p>
                    <P CLASS="CmTxt">The absolute risk reduction of 3% over 5 
                      years might appear unimpressively small. 2 factors, however, 
                      need to be taken into account. First, the results compare 
                      favorably with other current treatments to prevent stroke 
                      or heart disease. On the assumption that event rates would 
                      remain constant over the clinically more sensible period 
                      of 10 years, the study results suggest that treating 100 
                      elderly patients would prevent 6 strokes, 2 heart attacks, 
                      5 cases of congestive heart failure, and 2 deaths, whereas 
                      7 patients would have intolerable adverse effects from therapy.</p>
                    <P CLASS="CmTxt">The second factor to consider in interpreting 
                      these results is that the data were analyzed according to 
                      the groups to which patients were assigned, not according 
                      to whether patients actually took the medicine or achieved 
                      the target blood pressure. At 5 years, 90% of patients in 
                      the treatment group were<I> </I>on treatment but only two 
                      thirds achieved their blood pressure goal, whereas 44% of 
                      patients in the control group were treated and one third 
                      were at goal. Thus, the results of this study underestimate 
                      the benefits of <I>successfully treating</I> isolated systolic 
                      hypertension.</p>
                    <P CLASS="CmTxt">These factors, when combined with the reasonable 
                      cost and convenience (once a day), suggest that the stepped-care 
                      treatment program is clinically worthwhile.</p>
                    <P CLASS="CmAuth1">Arthur T. Evans, MD, MPH<BR>
                      University of North Carolina at Chapel Hill<BR>
                      Chapel Hill, North Carolina, USA</p>
                    <HR SIZE=2 COLOR=#3399CC>
                    <br>
                    <table width="100%" border="0" bgcolor="6699cc">
                      <tr> 
                        <td><strong>Reference</strong></td>
                      </tr>
                    </table>
                    <P CLASS="CmRef">1. <B>Staessen J, Bulpitt C, Clement D, et 
                      al.</B> Relation between mortality and treated blood pressure 
                      in elderly patients with hypertension: report of the European 
                      Working Party on High Blood Pressure in the Elderly. BMJ. 
                      1989;298:1552-6.</p>
                    <P align="center" CLASS="CmRef"><strong>Reprinted with permission<br>
                      &copy; American College of Physicians- American Society 
                      of Internal Medicine</strong><br>
                    </p>
                    <P align="left" CLASS="CmRef"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a> 
                      <br>
                      <br>
                      <a name="Staessen"></a> </p>
                    <P CLASS="BEsection"><font color="3399cc">Therapeutics</font></p>
                    <table width="100%" border="0" bgcolor="6699cc">
                      <tr> 
                        <td><font size="4"><strong><a name="diureticsreducedcardiovasculardiseaseeventsindiabeticandnondiabeticpatients"></a>Review: 
                          Isolated systolic hypertension increases mortality and 
                          morbidity in elderly persons and should be treated</strong></font></td>
                      </tr>
                    </table>
                    <P CLASS="ACPSource">ACP Journal Club. 2000 Sept-Oct;133:41.<BR>
                    </p>
                    <P CLASS="Citation">Staessen JA, Gasowski J, Wang JG, et al. 
                      <b>Risks of untreated and treated isolated systolic hypertension 
                      in the elderly: meta-analysis of outcome trials.</b> Lancet. 
                      2000 Mar 11;355:865-72. </p>
                    <HR SIZE=2 COLOR=#3399CC> 
                    <P CLASS="AbsHd"><font color="3399cc">Questions</font></p>
                    <P CLASS="AbsTxt">In elderly persons, what are the risks associated 
                      with isolated systolic hypertension (<img src="../Assets/greaterthansign.gif" width="6" height="9"> 
                      160 mm Hg with diastolic blood pressure [BP] &lt; 95 mm 
                      Hg), and what is the magnitude of the benefit associated 
                      with treatment? </p>
                    <P CLASS="AbsHd"><font color="3399cc">Data sources</font></p>
                    <P CLASS="AbsTxt">Studies were identified from 10 published 
                      overviews and 2 reports from trialist collaborations.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Study selection</font></p>
                    <P CLASS="AbsTxt">Controlled trials were selected if elderly 
                      persons with isolated systolic hypertension were enrolled. 
                      Trials were excluded if all the study participants had comorbid 
                      conditions, such as stroke; if specialized care was compared 
                      with routine antihypertensive agents; and if the study was 
                      a preliminary evaluation for a larger study. </p>
                    <P CLASS="AbsHd"><font color="3399cc">Data extraction</font></p>
                    <P CLASS="AbsTxt">Data were extracted on study quality, patient 
                      characteristics, antihypertensive treatment, duration and 
                      length of follow-up, and outcomes (all-cause and cardiovascular 
                      mortality, cardiovascular complications, all strokes, and 
                      all coronary events). Strokes did not include transient 
                      ischemic attacks. Cardiovascular complications included 
                      coronary artery disease (myocardial infarction and sudden 
                      death), stroke, and vascular disorders. </p>
                    <P CLASS="AbsHd"><font color="3399cc">Main results</font></p>
                    <P CLASS="AbsTxt">8 trials (15 693 patients) were included. 
                      Mean age range was 62 to 76 years, median follow-up was 
                      3.8 years, prevalence of smoking at baseline was 16%, and 
                      31% of participants had <img src="file:///E|/VA/Tabs/../Assets/greaterthansign.gif" width="6" height="9">1 
                      cardiovascular complication at baseline. All-cause mortality 
                      was positively associated with systolic BP (P &lt; 0.001) 
                      and negatively associated with diastolic BP (P = 0.05): 
                      With any given increase in systolic BP, a lower diastolic 
                      BP increased the risk for death. For each 10-mm increase 
                      in systolic BP, an increase was shown in all-cause mortality 
                      (hazard ratio [HR] 1.26, 95% CI 1.13 to 1.40), cardiovascular 
                      death (HR 1.22, CI 1.06 to 1.40), cardiovascular events 
                      (HR 1.15, CI 1.04 to 1.28), and stroke (HR 1.22, CI 1.04 
                      to 1.40) but not coronary events (HR 1.07, CI 0.91 to 1.26). 
                      For each 5-mm Hg increase in diastolic BP, a decrease in 
                      all-cause mortality was found (HR 0.95, CI 0.89 to 1.00). 
                    </p>
                    <P CLASS="AbsTxt">With treatment, the mean reduction was 10.4 
                      (range 6.9 to 18.2) in systolic BP and 4.1 (range 2.3 to 
                      8.3) mm Hg in diastolic BP. An improvement in all outcomes 
                      was found when results for all trials were pooled (Table). 
                      Summary analysis showed that all outcomes improved with 
                      treatment even across subgroups based on sex, age, systolic 
                      BP, pulse pressure, previous cardiovascular complications, 
                      and smoking status. </p>
                    <P CLASS="AbsHd"><font color="3399cc">Main outcome measures</font></p>
                    <P CLASS="AbsTxt">Combined nonfatal and fatal stroke, nonfatal 
                      myocardial infarction (MI) or cardiac death, major coronary 
                      heart disease (CHD), and major CVD.</p>
                    <P CLASS="AbsHd"><font color="3399cc">Conclusion</font></p>
                    <P CLASS="AbsTxt">Isolated systolic hypertension and wide 
                      pulse pressure in elderly persons increase the risk for 
                      mortality and morbidity. Treatment reduces this risk. </p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="Grant">Source of funding: 
                      Not stated.</p>
                    <P CLASS="Reprint">For correspondence: Dr. J.A. Staessen, 
                      Studie-co&ouml;rdinatiecentrum, Laboratorium Hypertensie, 
                      Campus Gasthuisberg, Gebouw Onderwijs en Navorsing, Herestraat 
                      49, B-3000 Leuven, Belgium. FAX 32-16-347106. </p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="TablTitl">Treatment of 
                      isolated systolic hypertension in elderly persons*</p>
                    <table cellspacing=0 cellpadding=3 width="100%" border=0>
                      <tbody>
                        <tr valign=top> 
                          <th class=colhdl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Outcomes 
                            at mean 3.8 y </font></th>
                          <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Odds 
                            ratio reduction (95% CI) </font></th>
                          <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">NNT 
                            (CI) </font></th>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All-cause 
                            mortality </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">13% 
                            (2 to 22) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">59 
                            (55 to 64) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Cardiovascular 
                            mortality </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">18% 
                            (4 to 29) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">79 
                            (72 to 89) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
                            cardiovascular events </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">26% 
                            (17 to 34) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">26 
                            (25 to 27) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
                            stroke events </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">30% 
                            (18 to 41) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">48 
                            (45 to 51) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
                            coronary events </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">23% 
                            (10 to 34) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">64 
                            (59 to 70) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                      </tbody>
                    </table>
                    <P CLASS="TablFootn"><font class=textblack 
      face="arial, helvetica, sans-serif" size=2><font 
      class=pageboldgrn size=2>*Abbreviations defined in <a 
      href="../Assets/Glossary2.html" target="_blank">Glossary</a>. 
                      1 trial was not a randomized controlled trial; reanalysis 
                      without this trial did not alter outcomes significantly.</font></font></p>
                    <hr size=2 color=#3399CC> 
                    <P CLASS="CmHd"><font color="3399cc">Commentary</font></p>
                    <P CLASS="CmTxt">Clinicians, be comforted! This sophisticated 
                      meta-analysis by Staessen and colleagues confirms what we 
                      already know: Systolic BP better predicts cardiovascular 
                      events than does diastolic BP, and absolute 5-year benefits 
                      of antihypertensive drug therapy are greater among persons 
                      with higher baseline risks, such as men, older adults, and 
                      persons with known cardiovascular disease. It also confirms 
                      several observational studies that show that wider pulse 
                      pressure—a measure dependent on ventricular ejection, timing 
                      of blood pressure waves, and arterial stiffness—is associated 
                      with higher baseline risks. </p>
                    <P CLASS="CmTxt">Should we now routinely use pulse pressure 
                      rather than systolic and diastolic BP measurements alone? 
                      Not yet. First, for those who rely on risk assessment to 
                      determine when benefits of treatment are likely to outweigh 
                      harms, we need changes in current risk-assessment tools 
                      to incorporate pulse pressure. Second, antihypertensive 
                      agents have multiple and heterogeneous effects, and the 
                      pathophysiology of hypertension is complex; all agents are 
                      not equivalent despite equivalent BP reduction (1). We do 
                      not yet know whether differences in drug benefits are caused 
                      by differences in reducing pulse pressure. </p>
                    <P CLASS="CmTxt">Active research to improve evidence-based 
                      care of patients with hypertension is alive and well. The 
                      results of these studies are still subject to change. What 
                      will the bottom line be? Clinicians, stand by! </p>
                    <P CLASS="CmAuth1">Ronald T. Ackermann, MD<br>
                      Cynthia D. Mulrow, MD <BR>
                      Audie L. Murphy Memorial Veterans Hospital<BR>
                      San Antonio, Texas, USA</p>
                    <HR SIZE=2 COLOR=#3399CC>
                    <br>
                    <table width="100%" border="0" bgcolor="6699cc">
                      <tr> 
                        <td><strong>Reference</strong></td>
                      </tr>
                    </table>
                    <P CLASS="CmRef">1. <b>ALLHAT Collaborative Research Group</b>. 
                      Major cardiovascular events in hypertensive patients randomized 
                      to doxazosin vs chlorthalidone: the Antihypertensive and 
                      Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 
                      JAMA. 2000;283:1967-75.</p>
                    <P CLASS="CmRef"><font class=textblack 
      face="arial, helvetica, sans-serif" color=#000000 size=2><font 
      class=pageboldgrn color=#009982 size=2><font 
      class=copyrightblue face="arial, sans-serif" color=#3399cc 
      size=1>Copyright &copy;2001 American College of Physicians – American Society 
                      of Internal Medicine</font> </font></font></p>
                    <P align="center" CLASS="CmRef"><font class=textblack 
      face="arial, helvetica, sans-serif" color=#000000 size=2><font 
      class=pageboldgrn color=#009982 size=2><strong><font color="#000000">Reprinted 
                      with permission<br>
                      &copy; American College of Physicians- American Society 
                      of Internal Medicine</font></strong><br>
                      </font></font></p>
                    <P align="left" CLASS="CmRef"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></p>
                    </td>
                </tr>
              </table>
              <p class="BEsection" align="right">&nbsp;</p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="528ece"> 
            <div align="center"><font size="+1" color="#FFFFFF">Please Report 
           
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
